ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026
Multicenter study on electrical performance and predictive indicators in aveir VR pacemaker recipients.
Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is limited evidence regarding the Aveir VR leadless pacemaker in mainland China, and the intraoperative electrical indicators linked to a favorable chronic pacing capture threshold (PCT) are not clearly defined.
methodsThis retrospective study across multiple centers involved 100 patients from Sichuan Province who received Aveir VR implants between January 2023 and December 2025, with electrical data available for evaluation at least one month after implantation.Chronic PCT was considered excellent if it was ≤ 0.5 V at 0.4 ms during the first device check after at least one month.Intraoperative predictors were identified using multivariable logistic regression.Receiver Operating Characteristic(ROC) analysis with bootstrap validation (500 replicates) was used to assess discrimination, and generalized additive models (GAMs) were employed to evaluate nonlinearity.
resultsIn 100 patients, the device implantation was successful with no significant complications, and 66 of them (66%) achieved excellent chronic PCT after a median follow-up period of 134 days. PCT improved from 0.76 ± 0.49 V at end of procedure to 0.63 ± 0.24 V at follow-up.Tether-phase R-wave sensing was independently associated with excellent chronic PCT (adjusted OR 1.27, 95% CI 1.06-1.51; P = 0.009). Tether-phase sensing showed modest discrimination (bias-corrected AUC 0.64, 95% CI 0.52-0.75). The 5.85 mV cutoff yielded sensitivity 68.3%, specificity 68.8%, PPV 80.4%, and NPV 53.7%. GAM indicated a nonlinear association (P for nonlinearity = 0.009).
conclusionsIn this cohort from mainland China, the implantation of Aveir VR was both feasible and safe, demonstrating stable short-term electrical performance. The sensing amplitude of the R-wave in the tether phase appears to be an additional intraoperative marker connected to excellent chronic PCT. Before recommending a specific cutoff for regular use, standardized long-term follow-up and external validation are necessary. Among 100 Aveir VR recipients in Chinese mainland, tether-phaseR-wave sensing was associated with excellent chronic PCT and demonstrated modestdiscriminative ability, indicating its potential role as a complementary intraoperativemarke.
Indexed as
Identifiers
42684646What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.